Peptide Design
and Optimization

Rational peptide design starts with understanding the biological context. If the goal is to mimic a protein-protein interaction, the starting point is typically a crystal structure or computational model of the interface, from which key contact residues are identified and extracted into a minimal peptide sequence. If the goal is de novo design—creating a peptide that binds a target without a natural template—the starting point is the target surface itself, using computational tools to design complementary sequences.

Sequence-activity relationships (SAR) drive iterative optimization. Alanine scanning identifies which residues are essential for activity. Positional scanning with natural and non-natural amino acids reveals tolerance at each position and identifies substitutions that improve binding, selectivity, or stability. Truncation studies define the minimal pharmacophore—the shortest sequence that retains full activity. Each round of SAR narrows the design space and builds a quantitative understanding of how sequence maps to function.

Unmodified linear peptides face two major liabilities: proteolytic degradation and conformational flexibility. A range of chemical modifications address these challenges. Cyclization—head-to-tail, disulfide, lactam, or stapled—constrains the peptide backbone, reducing conformational entropy and often improving both binding affinity (by pre-organizing the binding conformation) and protease resistance (by eliminating accessible termini and cleavage sites). Hydrocarbon stapling, which crosslinks side chains on the same face of an alpha helix, has been particularly successful for stabilizing helical peptides that target intracellular protein-protein interactions.

D-amino acid substitution replaces individual L-amino acids with their mirror-image counterparts. Because most mammalian proteases are stereospecific for L-amino acids, a single D-amino acid substitution at a susceptible cleavage site can dramatically improve plasma stability without significantly altering binding if the substitution is outside the binding interface. N-methylation of backbone amides similarly blocks protease recognition while also improving membrane permeability—a property relevant for peptides targeting intracellular proteins.

PEGylation—covalent attachment of polyethylene glycol chains—increases hydrodynamic radius, which reduces renal clearance and extends circulating half-life. The trade-off is reduced potency if the PEG chain sterically interferes with target binding, so PEGylation site selection requires careful consideration of the binding interface. Alternatives to PEG, including XTEN polypeptide fusions, albumin-binding peptides, and fatty acid conjugation (as used in semaglutide), achieve similar half-life extension through different mechanisms and may be preferred depending on the application.

Computational tools have transformed peptide design from a purely empirical exercise to a guided optimization process. Structure prediction algorithms (AlphaFold2, ESMFold, Boltz-2) generate models of peptide-target complexes that inform rational design decisions. Molecular dynamics simulations evaluate conformational stability and identify flexible regions that may benefit from cyclization. Machine learning models trained on binding data predict affinity changes from sequence mutations, enabling virtual screening of thousands of variants before any peptide is synthesized. The most effective peptide design workflows integrate computational prediction with experimental validation in iterative cycles, using each round of experimental data to refine the computational models and guide the next round of design.